Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder Cancer

Abstract

No AccessJournal of UrologyClinical Urology: Original Article1 Jul 1996Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder Cancer Erkki Rintala, Kari Jauhiainen, Eero Kaasinen, Martti Nurmi, and Olof Alfthan Erkki RintalaErkki Rintala , Kari JauhiainenKari Jauhiainen , Eero KaasinenEero Kaasinen , Martti NurmiMartti Nurmi , and Olof AlfthanOlof Alfthan View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65936-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We attempted to prove if alternating chemoprophylactic and immunoprophylactic instillations improved efficacy and decreased toxicity in patients with recurrent superficial bladder cancer. Materials and Methods: A total of 188 patients with rapidly recurring stage Ta or T1 cancer was randomly treated with mitomycin C (group 1) or alternating mitomycin C and Pasteur strain bacillus Calmette-Guerin (BCG) instillations (group 2) for 2 years. Mean followup was 34 months. Results: Median times to initial recurrence were 12 months in group 1 and 7 months in group 2 (p = 0.976), and treatment failed in 21.5 percent and 18.9 percent, respectively. Recurrence rates during the instillation period were 1.01 in group 1 and 0.86 in group 2 (p = 0.376). There was no difference in the disease-free interval between the 2 groups (p = 0.976). Instillations were discontinued because of adverse effects in 6 cases (6 percent) in both groups. Conclusions: Efficacy of alternating mitomycin C and BCG was equal to mitomycin C monotherapy, and both methods were effective in prophylaxis of recurrent papillary bladder cancer. Less toxicity occurred in the alternating treatment group compared to earlier BCG monotherapy results. References 1 : Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol.1989; 142: 719. Link, Google Scholar 2 : Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Brit. Med. J.1988; 296: 1759. Google Scholar 3 : Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol.1990; 143: 502. Link, Google Scholar 4 : A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitionalcell carcinoma of the bladder. New Engl. J. Med.1991; 325: 1205. Google Scholar 5 : Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur. Urol.1991; 20: 19. Crossref, Medline, Google Scholar 6 : Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J. Urol.1995; 154: 2050. Link, Google Scholar 7 : Intravesical instillation of Adriamycin. A model for standardization of the chemotherapy. Eur. Urol.1980; 6: 218. Google Scholar 8 : Intravesical cytostatics: pH-dependence of antitumour activity. Urol. Res.1985; 13: 19. Google Scholar 9 : Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients. J. Urol.1985; 134: 1107. Link, Google Scholar 10 : Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta-T1) bladder cancer. Brit. J. Urol.1987; 60: 54. Google Scholar 11 : Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J. Urol.1990; 144: 68. Link, Google Scholar 12 : Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol.1988; 6: 1450. Google Scholar 13 : Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol.1993; 27: 355. Google Scholar 14 : Cytostatic effect of different strains of bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alfa. Urol. Res.1992; 20: 215. Google Scholar 15 : A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol., part 21995; 153: 929. Abstract, Google Scholar 16 : A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol.1993; 149: 749. Link, Google Scholar 17 : Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol.1992; 147: 596. Link, Google Scholar 18 : Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol.1985; 134: 40. Link, Google Scholar 19 : A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol.1987; 5: 441. Crossref, Medline, Google Scholar 20 : Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer. J. Urol.1988; 139: 941. Link, Google Scholar 21 : BCG for carcinoma in situ. Eur. Urol.1992; 21: 30. Google Scholar Department of Urology, Helsinki University Central Hospital, Helsinki, Finland.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byChen F, Zhang G, Cao Y, Payne R and See W (2007) Bacillus Calmette-Guerin Inhibits Apoptosis in Human Urothelial Carcinoma Cell Lines in Response to Cytotoxic InjuryJournal of Urology, VOL. 178, NO. 5, (2166-2170), Online publication date: 1-Nov-2007.SYLVESTER R, van der MEIJDEN A and LAMM D (2018) Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, VOL. 168, NO. 5, (1964-1970), Online publication date: 1-Nov-2002.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.DUGGAN B, KELLY J, KEANE P and JOHNSTON S (2018) MOLECULAR TARGETS FOR THE THERAPEUTIC MANIPULATION OF APOPTOSIS IN BLADDER CANCERJournal of Urology, VOL. 165, NO. 3, (946-954), Online publication date: 1-Mar-2001.KAASINEN E, RINTALA E, PERE A, KALLIO J, PUOLAKKA V, LIUKKONEN T and TUHKANEN K (2018) WEEKLY MITOMYCIN C FOLLOWED BY MONTHLY BACILLUS CALMETTE-GUERIN OR ALTERNATING MONTHLY INTERFERON-α2B AND BACILLUS CALMETTE-GUERIN FOR PROPHYLAXIS OF RECURRENT PAPILLARY SUPERFICIAL BLADDER CARCINOMAJournal of Urology, VOL. 164, NO. 1, (47-52), Online publication date: 1-Jul-2000.ALI-EL-DEIN B, NABEEH A, ISMAIL E and GHONEIM M (2018) SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDYJournal of Urology, VOL. 162, NO. 2, (339-342), Online publication date: 1-Aug-1999.WITJES J, CARIS C, MUNGAN N, DEBRUYNE F and WITJES W (2018) RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 160, NO. 5, (1668-1672), Online publication date: 1-Nov-1998. Volume 156Issue 1July 1996Page: 56-60 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.Metrics Author Information Erkki Rintala More articles by this author Kari Jauhiainen More articles by this author Eero Kaasinen More articles by this author Martti Nurmi More articles by this author Olof Alfthan More articles by this author Expand All Advertisement PDF downloadLoading ...